FSD-201
- Generic Name
- FSD-201
Safety and Efficacy of FSD201 for the Treatment of Chronic Pain Associated With Idiopathic MCAS (MCAD)
Phase 2
Terminated
- Conditions
- Mast Cell Activation Disorder IdiopathicMast Cell Activation Syndrome
- Interventions
- Drug: Placebo
- First Posted Date
- 2022-12-15
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- FSD Pharma, Inc.
- Target Recruit Count
- 2
- Registration Number
- NCT05652907
- Locations
- ๐บ๐ธ
Saint Charles Clinical Research, Weldon Spring, Missouri, United States
๐จ๐ฆToronto Rehabilitation Institute, Toronto, Ontario, Canada
๐บ๐ธNorman Marcus Pain Institute, New York, New York, United States
Ultramicronized Palmitoylethanolamide (PEA) Treatment in Hospitalized Participants With COVID-19
Phase 2
Terminated
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2022-12-05
- Lead Sponsor
- FSD Pharma, Inc.
- Target Recruit Count
- 53
- Registration Number
- NCT04619706
- Locations
- ๐บ๐ธ
Kingsport, Tennessee, Kingsport, Tennessee, United States
๐บ๐ธButte, Montana, Butte, Montana, United States
๐บ๐ธAmarillo, Texas, Amarillo, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
ยฉ Copyright 2025. All Rights Reserved by MedPath